Dr Magda Dineva

Senior Patent Attorney

European Patent Attorney; PhD Chemistry; MSc Biotechnology/ Bio-organic Chemistry; MSc in Management of Intellectual Property and Certificate in Intellectual Property Law, from Queen Mary College, University of London.

Email Me


Magda specialises in the fields of life sciences and chemistry, handling a wide range of biotechnology, pharmaceutical and chemical subject matter including biopharmaceuticals, antibody and peptide therapeutics, personalised medicine, gene silencing and therapy, epigenetics, sequencing and stem cell technologies, antimicrobial formulations, nutraceuticals, plant biotechnology, microfluidics, diagnostics, medical devices, polymer compositions, consumer goods and healthcare products.

Her work involves patent drafting and prosecution, EPO oppositions and appeals, patent landscape analyses for freedom to operate and patentability, infringement risk assessments and due diligence, and Supplementary Protections Certificates.  She has been working for clients ranging from individual inventors and academia to large multinationals.

Magda has a technical background in chemistry (PhD) and biotechnology (MSc). Prior to joining the patent attorney profession in 2010, Magda worked as a senior scientist at the University of Cambridge and lead research and development of point-of-care molecular diagnostics.

As a co-founder of a spin-off company from the University of Cambridge, Magda worked on building and managed a global IP portfolio of patents and trademarks.  Her work as an in-house IP manager included invention harvesting and coordinating national and foreign filings and prosecution strategies. Related inventions received the EPO European Inventor Award in the SME category.  Related inventions (EP1301627, EP1301628, EP1301629, EP1325151, EP1336105) received the EPO European Inventor Award in the SME category, and had been used for the development of a new point‑of‑care device for coronavirus testing,
“The 90 minute game changer”: https://www.epo.org/news-events/in-focus/fighting-coronavirus/inventors-against-coronavirus.html.

Selected publications

Simple Amplification-Based Assay: A Nucleic Acid Based Point-of-Care Platform for HIV-1 Testing; Journal of Infectious Diseases (2010), 201 Suppl. 1: S65-72. DOI: 10.1086/650385

A new generation of point-of-care rapid tests; Horizons in medicine 20, Royal College of Physicians, December 2008

Sample preparation: a challenge in the development of point-of-care nucleic acid-based assays for resource-limited settings; Analyst (2007), 132: 1193-1199

Simultaneous Visual Detection of Multiple Viral Amplicons by Dipstick Assay; J Clinical Microbiology (2005), 43(8): 4015–4021

Life Sciences Team

Our Life Sciences team are hugely experienced in the application of legal knowledge within a broad range of commercial scenarios and practice areas.